Related Experiment Video
Updated: Jan 15, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?
Emily J Erbelding1, Jeanne M Marrazzo2
1Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Abstract:
The National Institute of Allergy and Infectious Diseases has funded a clinical trial infrastructure to advance products and strategies to improve treatment and prevention of infectious diseases. This infrastructure includes dedicated research clinics, such as the Vaccine and Treatment Evaluation Units (VTEUs). For more than 6 decades, the VTEUs have maintained quality systems to advance investigational products to licensure by conducting trials that de-risk private sector investment in clinical development. They have developed novel clinical trial approaches, such as controlled human challenge models, responded rapidly to pandemic threats, engaged impacted communities across a variety of diseases, and provided mentorship and training to the next generation of clinical investigators.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Preclinical Development: Overview
Vaccinations
Tumor Immunotherapy

